Testing stopping or extending immune treatment to prevent infections
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial studies whether people with certain blood cancers can safely stop their immune support medicine (immunoglobulin, also called Ig) or whether they should continue. It also tests antibiotic prevention strategies to reduce the risk of serious infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older.
- You have chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin lymphoma.
- You’ve been on Ig (IV or under-the-skin) for infection prevention for more than 6 months.
- Your care team thinks it’s reasonable for you to try either stopping or continuing Ig.
- You have a life expectancy of more than 12 months and can consent and follow study instructions.
- You must be able to take preventive (and emergency) medicines quickly if you get symptoms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a weekly infusion of a blood product called IgPro20 can help prevent infections in people with multiple myeloma who are already being treated with a bispecific antibody. If you qualify, you will receive the study treatment and be monitored for safety and infection rates.
This Phase 3 study tests whether XEMBIFY (an immune protein therapy) plus standard medical treatment can better prevent serious or repeated infections. It is for people with certain cancers of blood/immune systems who are already having trouble with infections.
This trial tests whether it is safe to stop or extend immunoglobulin (Ig) therapy for people with low antibody levels, or if switching to preventive antibiotics works just as well to prevent infections.
This trial compares two treatments—antibiotics or immunoglobulin (a blood product with infection-fighting antibodies)—to see which better prevents infections in people with certain blood cancers like CLL, multiple myeloma, or non-Hodgkin's lymphoma.
This trial tests whether giving immunoglobulin to adults with low antibody levels can prevent infections. It aims to compare immunoglobulin with antibiotic therapy or no added treatment for people with blood conditions.
This study looks at whether a different dose of IVIg (antibody treatment through the vein) or adding antibiotics can help prevent infections in people with low antibody levels. It's for patients already on steady IVIg who cannot safely stop it.
Hear when a new Hypogammaglobulinemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.